Joseph R. Young - Nov 11, 2025 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
SVP, FINANCE, CHIEF ACCT OFFCR
Signature
/s/ Joseph R. Young
Stock symbol
VERA
Transactions as of
Nov 11, 2025
Transactions value $
-$396,479
Form type
4
Date filed
11/13/2025, 08:57 PM
Previous filing
Feb 20, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR C/O VERA THERAPEUTICS, INC., 2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE /s/ Joseph R. Young 2025-11-13 0001861684

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Sale -$436K -15K -23.87% $29.06 47.8K Nov 11, 2025 Direct F1, F2
transaction VERA Class A Common Stock Options Exercise $39.4K +10K +20.9% $3.94 57.8K Nov 13, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERA Stock Option (right to buy) Options Exercise $0 -10K -17.07% $0.00 48.6K Nov 13, 2025 Class A Common Stock 10K $3.94 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.03 to $29.17, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F2 Includes 893 ordinary shares acquired pursuant to the Company's 2021 Employee Stock Purchase Plan.
F3 1/4 of the shares subject to the option vest on March 9, 2022, and 1/48 of the shares vest monthly thereafter.